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 Chapter 49 
 Examination of PACAP During Lactation 
 Andrea  Tamas ,  Reka  A.  Vass ,  Zsuzsanna  Helyes ,  Katalin  Csanaky , 
 Zalan  Szanto ,  Jozsef  Nemeth , and  Dora  Reglodi 
 Abstract  Breast milk is a complex biological ﬂ uid that contains nutritional 
components and non-nutritive bioactive factors promoting survival and healthy 
development of the newborn. PACAP has important functions, as a bioactive fac-
tor, in reproductive and developmental processes. Shortly after its discovery, 
PACAP and its receptors were identiﬁ ed in normal and cancerous mammary gland 
samples. The present review summarizes data obtained in breast milk during dif-
ferent periods of lactation by radioimmunoassay. Our group showed, for the ﬁ rst 
time, that PACAP is present in the human milk at levels 5- to 20-fold higher than 
in the respective plasma samples. PACAP-like immunoreactivity (LI) is higher in 
colostrum compared to transitional and mature human milk samples. PACAP level 
seems stable until the 10th month of lactation and there after, a signiﬁ cant increase 
can be observed between samples obtained in the interval 11th–17th months of 
breastfeeding. The presence of PACAP can also be conﬁ rmed in milk and plasma 
samples from the most commonly used ruminant domestic animals (cow, sheep 
and goat), pasteurized cow milk and infant formula samples. Similarly to the 
human results, the concentration of PACAP in the milk whey is almost ten times 
higher than in the plasma of the respective animals, while pasteurized cow milk 
and infant formula samples contain PACAP-LI levels comparable to human milk 
samples. The exact function of PACAP in the milk is not known at the moment. 
We hypothesize that PACAP (1) is essential for the growth and development of the 
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newborn, (2) may be required for the development of the immune system and 
immunological microenvironment of the  gastrointestinal tract, and (3) could be 
important in the growth and function of the mammary gland. 
 Keywords  PACAP-like immunoreactivity •  Milk •  Lactation •  Mammary gland 
 Based on the recommendation of the World Health Organization the exclusive 
breastfeeding is the normative standard for infant feeding for the ﬁ rst 6 months of 
life [ 1 ,  2 ]. Human milk is a complex biological ﬂ uid [ 3 ,  4 ], it contains nutritional 
components and non-nutritive bioactive factors that promote survival and healthy 
development of newborn [ 5 ]. The nutritional components of human milk vary 
depending on maternal diet and the period of lactation. The mean macronutrient 
composition of the mature milk is approximately 0.9–1.2 g/dl for protein, 3.2–3.6 g/
dl for fat, and 6.7–7.8 g/dl for lactose. Many micronutrients are also present in the 
milk including vitamins A, B1, B2, B6, B12, D and iodine [ 5 ]. The deﬁ nition of the 
bioactive components of the nutrition is “the elements that affect biological pro-
cesses or substrates and hence have an impact on body function or condition and 
ultimately health” [ 6 ]. The bioactive factors in the human milk originate from 
different sources: (1) secreted by the mammary epithelium, (2) produced by cells 
carried within the milk, (3) drawn from maternal serum and transported across the 
mammary epithelium [ 5 ]. Several bioactive factors have been described in the milk, 
including different hormones (adrenal, gonadal, gastrointestinal, pituitary, hypotha-
lamic), growth factors, prostaglandins, immunoglobulins, cytokines, chemokines, 
and different neuropeptides [ 3 ,  5 ]. Before the isolation of pituitary adenylate cyclase 
activating polypeptide (PACAP) Werner et al. [ 7 ] described the presence of vasoac-
tive intestinal peptide (VIP), the neuropeptide structurally the closest to PACAP, in 
milk samples. 
 Shortly after the discovery of PACAP [ 8 ,  9 ], Skakkebaek et al. [ 10 ] investigated 
the occurrence and distribution of PACAP immunoreactivity in the mammary gland 
of lactating and non-lactating rats by radioimmunoassay and immunohistochemis-
try. They showed PACAP-immunopositive nerve ﬁ bers associated with blood ves-
sels and smooth muscle surrounding the lactiferous duct of the nipple. 
PACAP-immunoreactive ﬁ bers were present in the subepidermal connective tissue 
of the nipple, in the mammary parenchyma and around secretory alveoli. Although 
there was no signiﬁ cant change in PACAP-immunohistochemical level during preg-
nancy and lactation, the concentration of PACAP38-immunoreactivity was elevated 
in the extract of mammary gland during lactation [ 10 ]. Double immunostaining 
demonstrated that PACAP-immunoreactive ﬁ bers were co-localized with VIP and 
calcitonin gene-related peptide (CGRP) originated from the neurons of sensory gan-
glia indicating the role of PACAP in the transport of suckling stimuli centrally [ 10 ]. 
The presence of both PACAP mRNA and PACAP immunoreactivity was also 
demonstrated in human normal mammary gland samples and breast carcinoma 
[ 11 ]. Normal, peritumoral and tumoral mammary gland samples expressed both 
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preproPACAP mRNA and protein, the levels of which increased from normal to 
tumoral breast tissue. Immunohistochemistry showed PACAP-immunoreactivity both 
in normal and tumoral tissue in the alveolar epithelial cells, but not in the connective 
tissue. In tumoral samples duct-like structures of some invasive tumors expressed very 
strong PACAP-immunoreactivity supporting the important role of this peptide not 
only in physiological conditions but also in tumorigenesis [ 11 – 13 ]. 
 All three PACAP receptors (PAC1, VPAC1, and VPAC2) were identiﬁ ed in nor-
mal and cancerous human mammary glands [ 13 – 18 ]. Both mRNA and protein of 
VPAC1 and VPAC2 receptors, as well as different isoforms (null, hip/hop) of PAC1 
receptors were identiﬁ ed in normal, peritumoral, and tumoral breast tissue sam-
ples. In normal tissue immunoreactivity to all three PACAP receptors were located 
in the ductal and glandular epithelial cells. On the other hand, tumoral tissue 
expressed stronger immunopositivity compared to normal tissue samples. There 
were no immunopositive signals in the connective tissue stroma of the mammary 
gland [ 14 ]. Zhang et al. [ 19 ] demonstrated that the analogs of VPAC1, VPAC2, and 
PAC1 receptors are potent, have biological activity and it is suitable of further 
evaluation for accurate PET imaging of benign and malignant lesions of human 
breast cancers. 
 In a set of earlier studies, our research group examined the changes of PACAP38- 
like immunoreactivity (LI) in the serum and milk samples of different species dur-
ing pregnancy and lactation. First we investigated the concentration of PACAP38 in 
human plasma of healthy male and female volunteers, pregnant women and lactat-
ing women having 1- to 6-month-old babies using radioimmunoassay (RIA) analy-
sis [ 20 ,  21 ]. We found relatively small interindividual differences among healthy 
volunteers (both sexes, age between 20 and 40 years), there were no signiﬁ cant 
differences between PACAP38 level of females with different age or hormone cycle. 
However, in the second and third trimester of pregnancy and during lactation a sig-
niﬁ cant elevation could be observed compared to the earlier gestational period and 
nonpregnant healthy volunteers [ 20 ,  21 ]. We detected 5- to 20-fold higher concen-
tration of PACAP38 in the milk whey compared to the respective plasma samples 
[ 20 ]. Similarly to our results numerous studies measured higher concentration of 
bioactive factors in the milk than in the plasma. Several hormones such as estrogen, 
gonadotropin releasing hormone (GnRH), thyrotropin releasing hormone, VIP, 
somatostatin, bombesin, neurotensin, oxytocin, prolactin, and different growth fac-
tors such as insulin-like, epidermal, transforming growth factors are present in 
higher concentrations in the milk than in the plasma [ 3 ]. 
 It is well known that the composition of milk is changing during lactation based 
on the requirements of the newborns [ 5 ,  22 ]. Therefore, we next investigated the dif-
ferences in PACAP38-LI in human milk samples from different periods of lactation. 
We collected colostrum samples at the beginning of lactation (1–3 days), transitional 
milk at fourth day of lactation, and mature milk samples every month during the 
whole period of lactation (1–17 months). Similarly to earlier results showing higher 
levels of different bioactive factors and nutrients in the colostrum we found signiﬁ -
cantly higher PACAP38-LI in the colostrum samples compared to transitional and 
mature milk samples [ 23 ]. Higher levels of hormones, growth factors, oligosaccharides, 
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cytokines, and immune regulating factors in the colostrum have important role in the 
development of the immune system and protective effects in allergic and inﬂ amma-
tory disorders [ 24 – 26 ]. The ﬁ rst 6 months of lactation have special importance for 
the development of the newborn, therefore, the WHO recommends exclusive breast-
feeding in the ﬁ rst half year of life. We did not ﬁ nd signiﬁ cant alterations in the level 
of PACAP38-LI during the ﬁ rst 6 months of lactation. We measured a stable 
PACAP38-LI level until the tenth month and after a signiﬁ cant increase was observed 
in the samples from 11th to 17th months of lactation [ 23 ]. The composition of the 
milk also depends on the time that passes between the successive sucklings. At the 
beginning of the suckling the foremilk has lower fat content and later the hindmilk 
contains more fat and lactose. Several bioactive factors have different concentration 
in the foremilk compared to the hindmilk. Endothelin-1, ghrelin and cholesterol have 
higher level, and triglyceride, leptin, retinol have lower level in the foremilk com-
pared to hindmilk [ 27 ,  28 ]. However, we did not ﬁ nd signiﬁ cant difference in 
PACAP38-LI between foremilk and hindmilk samples similarly to atrial natriuretic 
peptide and granulocyte colony-stimulating factor [ 29 – 31 ]. 
 Investigation of bioactive factors in the milk of domestic animals has important 
nutritional value and agricultural signiﬁ cance [ 32 ]. Numerous studies investigated 
different growth factors, hormones in the milk of pig, cow, sheep and goats [ 33 – 38 ]. 
Therefore, we aimed to compare the PACAP38 level of milk and plasma samples 
from the most commonly used ruminant domestic animals: cow, sheep and goat. 
Similarly to our earlier human results the concentration of PACAP in the milk whey 
was almost ten times higher than in the plasma of the respective animals, and the 
PACAP38-LI did not change during the 3-month-period of lactation [ 39 ]. Fresh 
cow milk had similar PACAP content as human samples [ 31 ]. We also examined 
PACAP38-LI in the homogenates of sheep udder biopsies with RIA. Localization of 
PAC1 receptor was also investigated in the lactating and non-lactating sheep mam-
mary gland samples with immunohistochemistry compared to non-lactating human 
mammary gland samples. In the non-lactating human and sheep samples, a very 
weak PAC1 receptor immunopositivity was detected in the glandular epithelial cells 
[ 23 ]. In contrast, signiﬁ cantly increased PAC1 receptor expression was detected in 
lactating sheep mammary gland epithelial cells compared to non-lactating samples, 
while the surrounding connective tissue remained unstained in all samples [ 23 ,  39 ]. 
RIA examination of the homogenates of lactating mammary gland samples from 
sheep showed signiﬁ cantly higher PACAP38-LI 7 days after delivery compared 
with samples from postpartum 30th days [ 39 ]. 
 When mother’s milk is unavailable cow-milk based infant formulas are neces-
sary to use. Therefore, in the next step we aimed to measure the PACAP38-LI in 
pasteurized cow milk and two basic infant formulas, the hypoantigenic and the non- 
hypoantigenic infant formula samples by RIA. The infant formula samples contain 
minerals, vitamins, lactose, fat and some proteins for example parathyroid hormone- 
like peptide [ 40 ], parathyroid hormone-related protein [ 41 ], but most of the proteins 
are hydrolyzed during the preparation process. There are many bioactive factors, 
which cannot be detected in the infant formula, for example insulin-like growth fac-
tors, GnRH, antibodies, and enzymes [ 3 ,  41 ]. In our earlier experiment we showed 
that the pasteurized cow milk and infant formula samples contain PACAP38-LI at 
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levels comparable to human milk samples. This observation means that because of 
the low molecular weight PACAP might withstand hydrolysis and the manufactur-
ing processes. Interestingly, we detected higher PACAP level in the hypoanti-
genic formulas compared to non-hypo antigenic formula samples. These results 
suggest that PACAP38 could have a carrier not yet known in the milk (such as 
ceruloplamin) and during the extensive hydrolysis it might be released from the 
carrier molecule [ 31 ]. 
 The exact function of PACAP in the milk is not known at the moment. We hypoth-
esize that PACAP (1) is essential for the growth and development of the newborn; 
(2) may be required for the development of the immune system and immunological 
microenvironment of the gastrointestinal tract; (3) could be important in the growth 
and function of mammary gland (Fig.  49.1 ).
 It is well known that PACAP plays a very important role in the development of 
the nervous system and other internal organs. PACAP is a potent neurotrophic fac-
tor, it plays an important role in neurogenesis, myelinization, neuronal differentia-
tion and migration. A separate chapter of this book summarizes the function of 
PACAP in neuronal development (Chap.  6 . Watanabe et al.). The source of PACAP 
required for development of the nervous system of the newborn could be partially 
originating from the milk. 
 PACAP has well known immunomodulatory effects (Chap.  40 . Delgado et al.). 
We suggest that as other bioactive components of milk, PACAP has a role in protecting 
newborns against infections and stimulating the development of the immune system 
and immunological microenvironment of the gastrointestinal tract. 
 The third possible function of PACAP in the human breast is the regulation of 
secretion and growth of the mammary gland. Apoptosis plays an important role in the 
 Fig. 49.1  Possible functions of PACAP in the breast milk during lactation 
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involution of mammary gland, while during lactation the expression of antiapoptotic 
factors is elevated by different bioactive factors. PACAP is a potent antiapoptotic fac-
tor, and it has inﬂ uence on cytokines, chemokines, angiogenic factors, and different 
hormones (estrogen, progesterone, prolactin, and oxytocin) which are also involved in 
the regulation of lactation [ 42 ,  43 ]. Intravenous PACAP injection increases the prolac-
tin level in human plasma supporting the role of PACAP during lactation [ 44 ]. Earlier 
we examined the effect on the lactogenic hormone-induced terminal differentiation of 
HC11 mouse mammary epithelial cells. We treated mouse HC11 cells with lactogenic 
hormones (dexamethasone, insulin, and prolactin) and we measured the β-casein 
expression to show cell differentiation. We demonstrated that PACAP had no effect on 
cell differentiation, as PACAP treatment did not inﬂ uence the β-casein expression. 
Mouse cytokine and angiogenesis arrays were also used to show the PACAP-induced 
changes in secreted cytokines, growth and angiogenic factors in differentiated and 
non-differentiated cells, where PACAP was able to decrease the levels of amphiregu-
lin and epidermal growth factor, which may have physiological implications in the 
development and progression of mammary gland diseases [ 45 ]. 
 The oral bioavailability of PACAP originating from milk is not known at the 
moment. PACAP has a very short half-life (minutes) in the plasma; exogenous 
PACAP38 is rapidly degraded in the presence of dipeptidyl peptidase IV [ 46 ,  47 ]. In 
contrast to the plasma samples PACAP was stable in milk samples, because we could 
detect PACAP38-LI from milk samples stored in −20 °C without protease inhibitor 
treatment several days or weeks after the collection. It is known that the mammary 
gland produces different protease inhibitors which are responsible for the stability of 
different bioactive proteins and peptides in the milk. In neonates the proteolytic 
enzymes (including dipeptidyl peptidase) have lower activity and the intestinal epi-
thelium has higher permeability for the macromolecules, and therefore, we suggest 
that PACAP could be utilized during breastfeeding. 
 Taken together, the experimental data suggest that PACAP could have an important 
role during lactation based on its antiapoptotic, immunomodulatory, and neurotrophic 
effects, but further examinations are necessary to describe the exact functions. 
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